Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation

Circulation. 2010 Apr 27;121(16):1868-77. doi: 10.1161/CIR.0b013e3181d34114. Epub 2010 Feb 23.
No abstract available

Publication types

  • Consensus Development Conference

MeSH terms

  • Advisory Committees
  • American Heart Association
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Myocardial Infarction / epidemiology*
  • Prevalence
  • Risk Factors
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • United States / epidemiology

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone